Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Billaud

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Medecine Sciences : M/S|March 20, 2026
[Are we giving ourselves the means for an ambitious cancer prevention policy?]Marc Billaud
Medecine Sciences : M/S|January 8, 2013
[Intratumor heterogeneity, a Darwinian stumbling block towards personalized medicine?]Marc Billaud
FEBS Letters|December 28, 2010
The LKB1/AMPK polarity pathwayVincent Mirouse, Marc Billaud
Cancer Research|October 27, 2011
Is Co-option a prevailing mechanism during cancer progression?Marc Billaud, Massimo Santoro
Bulletin Du Cancer|July 1, 2025
[In (scientific) search for already known risk factors]Pierre Sujobert, Marc Billaud
Medecine Sciences : M/S|September 6, 2015
[The invention of personalized medicine, between technological upheavals and utopia]Marc Billaud, Xavier Guchet
Science'S STKE : Signal Transduction Knowledge Environment|September 20, 2007
Dialogue between LKB1 and AMPK: a hot topic at the cellular poleChristelle Forcet, Marc Billaud
Cancer Biology & Therapy|June 29, 2010
Close encounters of a novel kind: a multi-targeted cancer drug meets a metabolic sensorMarc Billaud, Benoît Viollet
Developmental Cell|December 15, 2010
Primary cilia bend LKB1 and mTOR to their willNicolas Aznar, Marc Billaud
Frontiers in Endocrinology|July 5, 2017
Desynchronization of Circadian Clocks in Cancer: A Metabolic and Epigenetic ConnectionKiran Padmanabhan, Marc Billaud
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Medecine Sciences : M/S|March 20, 2026
[Are we giving ourselves the means for an ambitious cancer prevention policy?]Marc Billaud
Medecine Sciences : M/S|January 8, 2013
[Intratumor heterogeneity, a Darwinian stumbling block towards personalized medicine?]Marc Billaud
FEBS Letters|December 28, 2010
The LKB1/AMPK polarity pathwayVincent Mirouse, Marc Billaud
Cancer Research|October 27, 2011
Is Co-option a prevailing mechanism during cancer progression?Marc Billaud, Massimo Santoro
Bulletin Du Cancer|July 1, 2025
[In (scientific) search for already known risk factors]Pierre Sujobert, Marc Billaud
Medecine Sciences : M/S|September 6, 2015
[The invention of personalized medicine, between technological upheavals and utopia]Marc Billaud, Xavier Guchet
Science'S STKE : Signal Transduction Knowledge Environment|September 20, 2007
Dialogue between LKB1 and AMPK: a hot topic at the cellular poleChristelle Forcet, Marc Billaud
Cancer Biology & Therapy|June 29, 2010
Close encounters of a novel kind: a multi-targeted cancer drug meets a metabolic sensorMarc Billaud, Benoît Viollet
Developmental Cell|December 15, 2010
Primary cilia bend LKB1 and mTOR to their willNicolas Aznar, Marc Billaud
Frontiers in Endocrinology|July 5, 2017
Desynchronization of Circadian Clocks in Cancer: A Metabolic and Epigenetic ConnectionKiran Padmanabhan, Marc Billaud
Pageof 6